|Bid||174.71 x 200|
|Ask||174.78 x 100|
|Day's Range||174.49 - 176.50|
|52 Week Range||119.37 - 189.48|
|PE Ratio (TTM)||35.42|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In the billion-dollar race to come up with the best way of detecting cancer by peering closely at the blood, a Redwood City company Wednesday said that it raised $360 million on its way to a potential initial public offering. Guardant Health Inc. said the round was led by a subsidiary of Japanese telecommunications company SoftBank Group and included Sequoia Capital, Khosla Ventures, Lightspeed Venture Partners, OrbiMed and 8VC as well as accounts managed by T. Rowe Price and Singapore's Temasek. The mix of traditional venture capital and crossover investors — typically private equity groups that often look to take companies public soon after their investments — hints at an IPO for four-year-old Guardant, especially since liquid biopsies have garnered lots of attention for their potential of detecting cancer early.
Why Exact Sciences, Illumina, and Vertex Pharmaceuticals are the best stocks in personalized medicine right now.
A new product launch and upbeat first-quarter results caused Illumina's stock to rally.